Eupraxia Pharmaceuticals (NASDAQ:EPRX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02, Zacks reports.

Eupraxia Pharmaceuticals Trading Up 0.6%

EPRX traded up $0.04 during mid-day trading on Tuesday, hitting $6.70. 181,022 shares of the stock were exchanged, compared to its average volume of 269,418. The firm’s fifty day moving average is $6.40 and its two-hundred day moving average is $7.20. Eupraxia Pharmaceuticals has a 1-year low of $5.04 and a 1-year high of $9.32. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The company has a market cap of $435.63 million, a PE ratio of -6.38 and a beta of 1.08.

Analyst Ratings Changes

EPRX has been the topic of a number of recent analyst reports. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in shares of Eupraxia Pharmaceuticals by 44.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock worth $438,000 after purchasing an additional 17,958 shares in the last quarter. Cibc World Market Inc. grew its holdings in shares of Eupraxia Pharmaceuticals by 287.0% in the fourth quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock valued at $437,000 after purchasing an additional 43,050 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $326,000. Bank of America Corp DE grew its holdings in shares of Eupraxia Pharmaceuticals by 262.9% in the third quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after purchasing an additional 33,018 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $223,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.